- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection
Lisa Sandmann 1 , Heiner Wedemeyer 2
Affiliations
Affiliations
1
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany.
2
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany; German Center for Infection Research (DZIF), Partner Side Hannover/Braunschweig. Electronic address: [email protected].
PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011
Abstract
Chronic hepatitis D virus (HDV) infection is the most severe form of viral hepatitis with high rates of end-stage liver disease and hepatocellular carcinoma. Therefore, effective antiviral treatment strategies are needed desperately. Until recently, antiviral treatment was limited to pegylated interferon-alpha. With the conditional approval of the entry inhibitor bulevirtide by the European Medicines Agency, new treatment options are now available. In addition, multiple other antiviral compounds are currently tested in clinical phase II and III trials and represent promising agents for the treatment of chronic HDV infection.
Keywords: Antiviral treatment; Bulevirtide; Hepatitis delta; Interferon; Interferon lambda; Nucleic acid polymers; siRNA.
Copyright © 2021 Elsevier Inc. All rights reserved. |
|